Rusfertide: Physiology and What Research Reports

What Rusfertide Is

Rusfertide, also identified in earlier literature as PTG-300, is a synthetic peptide engineered to act like hepcidin, the body's master iron-regulating hormone. Because it copies a natural hormone's action rather than blocking a receptor, it is usually described in the literature as a hepcidin mimetic. It has been administered subcutaneously in clinical studies, including a double-blind first-in-human study of an aqueous formulation in healthy volunteers (PMID 38785334) and a later evaluation of a lyophilized powder formulation, also given subcutaneously to healthy volunteers (PMID 39546273).

This page is for educational purposes only and is not medical advice; consult a licensed physician about any medical condition or treatment decision. Nothing here describes how a compound should be used.

Hepcidin and Ferroportin: The Underlying Physiology

Where hepcidin is produced

Hepcidin is a small peptide hormone made mainly by hepatocytes in the liver. Its production rises when body iron stores are high or when inflammation is present, and falls when iron is scarce or when the bone marrow is driving high rates of red cell production. Hepcidin is the signal that tells the body to stop releasing iron into the circulation.

What hepcidin does

Hepcidin acts on ferroportin, the only known cellular exporter of iron in humans. Ferroportin sits on the surface of duodenal enterocytes (which absorb dietary iron), macrophages (which recycle iron from senescent red cells), and hepatocytes (which store it). When hepcidin binds ferroportin, iron export is blocked and iron is effectively trapped inside those cells. Serum iron falls, transferrin saturation falls, and less iron reaches the bone marrow for haemoglobin synthesis.

Two clinical situations make this axis interesting. In HFE-related hereditary haemochromatosis, hepcidin signalling is deficient, so iron absorption continues unchecked and iron accumulates in tissues. In polycythemia vera, a myeloproliferative neoplasm, the bone marrow overproduces red cells; restricting iron availability is one way researchers have explored limiting that overproduction. A peptide that reproduces hepcidin's action is therefore a logical research tool in both settings.

How Rusfertide Is Measured and Studied

Because hepcidin mimetics act on iron trafficking rather than on a single symptom, studies track a cluster of laboratory markers. The pharmacology literature has combined pharmacokinetic sampling (plasma concentrations of the peptide over time) with pharmacodynamic readouts such as serum iron and transferrin saturation; a multiple-dose study in healthy subjects characterised subcutaneous rusfertide's pharmacokinetics, pharmacodynamics, safety and tolerability together in one design (PMID 39888264). In disease settings the dominant readout has been hematocrit and the number of therapeutic phlebotomies required, as used in a phase 2 trial in polycythemia vera (PMID 38381675).

What the Literature Reports

Polycythemia vera

In a phase 2 trial of patients with polycythemia vera who had required frequent phlebotomy, researchers reported that rusfertide controlled erythrocytosis, with a higher proportion of participants meeting the trial's response definition during a randomized withdrawal period on rusfertide than on placebo (PMID 38381675). A later report in patients with suboptimally controlled polycythemia vera described a rapid decrease in hematocrit after rusfertide administration (PMID 41175501). Both reports are consistent with the underlying physiology: limiting iron availability limits the substrate for haemoglobin synthesis and therefore red cell mass.

HFE-related hereditary haemochromatosis

An open-label, multicentre, proof-of-concept phase 2 trial evaluated rusfertide for the treatment of iron overload in HFE-related haemochromatosis and reported effects on iron parameters and on the need for maintenance phlebotomy in the enrolled participants (PMID 37863080). Because the trial was open-label and designed as proof of concept, the authors framed the results as supporting further study rather than as definitive.

Healthy volunteers

The healthy-volunteer literature exists to characterise behaviour of the molecule rather than to treat anything. The first-in-human, double-blind study of an aqueous formulation described pharmacokinetics, pharmacodynamics and tolerability of subcutaneous rusfertide (PMID 38785334), a separate study characterised a lyophilized powder formulation given subcutaneously (PMID 39546273), and a multiple-dose study extended those observations to repeated subcutaneous administration (PMID 39888264).

Adverse Events: What Studies Report

In the phase 2 polycythemia vera trial, the study reported that injection-site reactions were the most common adverse events, and were predominantly of low grade (PMID 38381675). Tolerability was also a stated endpoint of the multiple-dose healthy-subject study, which assessed safety and tolerability alongside pharmacokinetics and pharmacodynamics of subcutaneous rusfertide (PMID 39888264), and of the first-in-human study in healthy volunteers (PMID 38785334). Cardiac safety was examined separately: a randomized, placebo- and positive-controlled crossover thorough QT study in healthy participants evaluated whether rusfertide affected cardiac repolarization (PMID 41033871).

Two cautions belong with any adverse-event summary. First, trial populations were selected and monitored, so reported event rates do not transfer to unmonitored settings. Second, iron restriction is the mechanism, not a side effect — which means iron and haematologic parameters were laboratory-monitored throughout the cited trials (PMID 37863080).

Why the Term Comes Up

Rusfertide appears in three overlapping conversations: haematology, where hepcidin mimetics represent a mechanistically new approach to iron-driven disease; peptide pharmacology, where it is a worked example of a peptide engineered for stability and subcutaneous delivery (PMID 39546273); and general peptide discussion, where the name circulates alongside unrelated compounds. It is a clinical investigational agent studied under trial protocols with physician oversight and laboratory monitoring — not a wellness compound, and not interchangeable with anything sold outside that setting.

Key Takeaways

• Rusfertide mimics hepcidin, the liver hormone that blocks ferroportin and restricts iron release into blood.
• Researchers reported control of erythrocytosis in polycythemia vera in a phase 2 trial (PMID 38381675) and rapid hematocrit reduction in suboptimally controlled disease (PMID 41175501).
• An open-label phase 2 trial studied it for iron overload in HFE-related haemochromatosis (PMID 37863080).
• Injection-site reactions were the most commonly reported adverse events in the polycythemia vera trial (PMID 38381675).

References

• Rusfertide for the treatment of iron overload in HFE-related haemochromatosis: an open-label, multicentre, proof-of-concept phase 2 trial (The Lancet Gastroenterology & Hepatology, 2023)
• Rusfertide, a Hepcidin Mimetic, for Control of Erythrocytosis in Polycythemia Vera (The New England Journal of Medicine, 2024)
• Multiple-Dose Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of Subcutaneous Rusfertide, a Hepcidin Mimetic, in Healthy Subjects (Clinical Pharmacology in Drug Development, 2025)
• Pharmacokinetics and Pharmacodynamics of Rusfertide, a Hepcidin Mimetic, Following Subcutaneous Administration of a Lyophilized Powder Formulation in Healthy Volunteers (Drugs in R&D, 2024)
• Pharmacokinetics, pharmacodynamics, and tolerability of an aqueous formulation of rusfertide (PTG-300), a hepcidin mimetic, in healthy volunteers: A double-blind first-in-human study (European Journal of Haematology, 2024)
• Rusfertide rapidly decreases hematocrit in patients with suboptimally controlled polycythemia vera (Leukemia Research, 2025)
• Evaluation of Rusfertide, a Hepcidin Mimetic, on Cardiac Repolarization: A Randomized, Placebo- and Positive-Controlled Crossover Thorough QT Study in Healthy Participants (Clinical Therapeutics, 2025)